Adjuvant Therapy for Melanoma Prolongs RFS.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-047
Abstract: The PD-1 inhibitor pembrolizumab may be an effective adjuvant therapy for patients with stage III melanoma. In a clinical trial, patients who received the drug had a 12-month recurrence-free survival rate of 75.4%, compared with… read more here.
Keywords: prolongs rfs; therapy melanoma; melanoma prolongs; therapy ... See more keywords